

Q1 2024 *Results*



- We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. •

Paul Hudson

Chief Executive Officer, Sanofi

Q1 2024 company sales

€10,464m

+6.7% at constant exchange rates

+2.4% on a reported basis

Q1 2024 business earnings per share

€1.78

-7.4% at constant exchange rates

-17.6% on a reported basis

Robust growth driven by portfolio transformation



Dupixent

€2,835m

+24.9%

at constant
exchange rates



Pharma launches

€606m

+90.5%

at constant
exchange rates



Vaccines

€1,177m

+5.6%

at constant
exchange rates



Other products

€4,321m

-7.9%

at constant
exchange rates



CHC

€1,525m

+9.0%

at constant
exchange rates

sanofi

Q1 2024 *Results*

Sales by geography

US
€4,316m

Europe
€2,480m

Rest of the World
€3,668m

Research & Development



3
regulatory approvals in Q1 2024

12
phase 3 data readouts
expected over 2024-2025

Sanofi Global Health Unit



506,130
patients treated in

31
low- and middle-income
countries since 2021

For further information on Q1 2024 results and definitions of financial indicators, please refer to the press release issued on April 25, 2024 at: www.sanofi.com/en/investors